The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.
Kenji Tamura
No relevant relationships to disclose
Jun Hashimoto
No relevant relationships to disclose
Hitoshi Tsuda
No relevant relationships to disclose
Masayuki Yoshida
No relevant relationships to disclose
Hideko Yamauchi
No relevant relationships to disclose
Kenjiro Aogi
No relevant relationships to disclose
Satoru Shimizu
No relevant relationships to disclose
Hiroji Iwata
No relevant relationships to disclose
Norikazu Masuda
No relevant relationships to disclose
Naohito Yamamoto
No relevant relationships to disclose
Kenichi Inoue
No relevant relationships to disclose
Shinji Ohno
No relevant relationships to disclose
Katsumasa Kuroi
No relevant relationships to disclose
Tamie Sukigara
No relevant relationships to disclose
Yasuhiro Fujiwara
No relevant relationships to disclose
Masashi Andoh
No relevant relationships to disclose